ACIP recommends routine use of mpox vaccine for at-risk adults, opening the door to potential 2024 launch
The CDC’s Advisory Committee on Immunization Practices (ACIP) has voted in favor of routine use of the mpox vaccine Jynneos, opening the door to potential commercial opportunities for its manufacturer.
Bavarian Nordic reported “overwhelming” interest in Jynneos amid the global mpox outbreak. The two-dose vaccine was one of the only interventions available and often the preferred one, though it was only recommended for at-risk individuals during an outbreak.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.